1. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1148,
1998,
Page 2-2
&NA;,
Preview
|
PDF (841KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
2. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1148,
1998,
Page 3-3
&NA;,
Preview
|
PDF (742KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
3. |
Interleukin-10 gene therapy has potential in arthritis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1148,
1998,
Page 4-4
&NA;,
Preview
|
PDF (708KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
4. |
Efavirenz offers new options in HIV infection |
|
Inpharma Weekly,
Volume &NA;,
Issue 1148,
1998,
Page 5-6
Wayne Elwood,
Preview
|
PDF (1675KB)
|
|
摘要:
Results from a landmark clinical study show that efavirenz [DMP 266; DuPont Merck], a potent and selective non-nucleoside HIV-1 reverse transcriptase inhibitor (NNRTI), is a valuable new anti-HIV agent, allowing effective suppression of viral load while sparing the early use of protease inhibitors in patients starting antiretroviral therapy. In Dupont Pharmaceuticals Study 006, the use of efavirenz in combination with 2 nucleoside reverse transcriptase inhibitors (NRTIs) suppressed viral load to undetectable levels in a greater percentage of patients compared with a currently used standard regimen of 2 NRTIs and a protease inhibitor, delegates were told at the 12th World AIDS Conference [Geneva, Switzerland; June 1998].
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
5. |
Lyme disease vaccines effective and well tolerated |
|
Inpharma Weekly,
Volume &NA;,
Issue 1148,
1998,
Page 7-7
&NA;,
Preview
|
PDF (744KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
6. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1148,
1998,
Page 8-8
&NA;,
Preview
|
PDF (732KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
7. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1148,
1998,
Page 9-9
&NA;,
Preview
|
PDF (761KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
8. |
Should the routine use of albumin cease? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1148,
1998,
Page 10-10
&NA;,
Preview
|
PDF (717KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
9. |
Finding the right niche for BPH therapies |
|
Inpharma Weekly,
Volume &NA;,
Issue 1148,
1998,
Page 11-12
Charles Bankhead,
Preview
|
PDF (1563KB)
|
|
摘要:
In the multicentre Veterans Affairs (VA) Cooperative Study, the &agr;-blocker terazosin proved superior to the 5&agr;-reductase inhibitor finasteride for the treatment of benign prostatic hyperplasia (BPH).1Adding finasteride to terazosin offered no symptomatic benefits above those obtained with the &agr;-blocker alone, and finasteride monotherapy proved not to be statistically better than placebo. Investigators are still trying to clarify the therapeutic niches for &agr;-blockers and for finasteride. This process continued at the recent American Urological Association meeting [San Diego, US; June 1998].
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
10. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1148,
1998,
Page 12-12
&NA;,
Preview
|
PDF (793KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|